ACTRT1

Across TCGA pan-cancer cohorts, ACTRT1 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated ACTRT1 data layer compared with 7 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ACTRT1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ACTRT1 expression acts as an unfavorable survival marker, although some lineages such as THYM and SCLC show a favorable association.

LIHC, STAD, and ESCA are the cancer types where ACTRT1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.480	0.710	<.001	72	view →
STAD	OS	Tertile	IV	0.074	0.496	.002	69	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
READ	DFS	Tertile	II,III,IV	0.144	0.526	.014	27	view →
THYM	DFS	Quartile	II,III,IV	1.000	0.663	.018	21	view →
SKCM	DFS	Tertile	IV	0.036	0.433	<.001	18	view →
HNSC	DFS	Tertile	III,IV	0.577	0.680	.021	18	view →
CHOL	OS	Tertile	All	0.136	0.710	.005	18	view →
LUAD	OS	Tertile	All	0.735	0.845	.019	12	view →
LUSC	DFS	Tertile	All	0.620	0.820	.018	12	view →
SCLC	OS	Median	IV	0.829	0.241	.005	12	view →
THCA	DFS	Tertile	III,IV	0.421	0.701	.047	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

ACTRT1–LIHC (OS)

Open the LIHC breakdown →